Appointment of Fionán Murray, as Group Sales Director
Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on extending digital services on top of existing Labskin physical services to rapidly grow the Labskin AI footprint.
As Managing Director of RinoCloud Fionán Murray oversaw the development of a range of software services dedicated to data management – its security, storage, curation and analysis – which generated interest from large blue-chip clients in Government, Financial Services, Healthcare and Scientific Research. Beta software deployments throughout 2017 have provided:
- GDPR data management compliance for government;
- Secure data collaboration between large financial services groups and their customers/distribution channels;
- Secure data curation and collaboration for research and development groups; and
- Big science data analysis using AI.
And what all this means for the future of Integumen…
These existing sales, marketing and distribution channels provide the opportunity for cross selling complementary digital and physical testing services currently being rolled out as part of the Labskin AI eco-system. This incorporates the data management and analytic services already built into Labskin AI by the RinoCloud integration.
Gerard Brandon, Chief Executive Officer, commented:
Over the last five years, Labskin has established itself as an approved supplier of products and services into a large portfolio of blue-chip skincare, pharma, personal care, wound care and health care clients across the US, EU and Asia. Fionán Murray brings extensive expertise in the sales, innovation, collation and maintenance of secure cloud-based sensitive scientific data and his appointment underpins our commitment to deliver sustained growth and drive value for our shareholders
Big data analytics is key to transforming the future of skin disease drug development which is ranked as the fourth most common cause of human illness. While drug companies still chase molecules for new blockbuster drugs, millions of people are suffering from skin related diseases today.
Revenues grew by 890% to £477,000 (unaudited), combined with revenues for RinoCloud, prior to their acquisition, Group revenues jumped 1,213% to £655,000
Integumen Annual Report at 31 December 2018
Integumen signs 3 contracts and continues to make rapid progress up the value chain by entering into larger contracts for Labskin AI services.
FY 2018 total revenue £502k increased 111% (FY 2017 : £238k);
FY 2018 revenue from continued operations £274k increased 294% (FY 2017 : £93k) following Labskin test kit sales move to full skin-care product test services;
FY 2018 EBITDA losses reduced by 12% to (£1.25m) (FY 2017: (£1.40m))
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials. Combined with human volunteers doubles number of skin tests possible saving time and money.